Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Salarius Pharmaceuticals, Inc. | flks20171231ex321.htm |
| EX-31.2 - EXHIBIT 31.2 - Salarius Pharmaceuticals, Inc. | flks20171231ex-312.htm |
| EX-31.1 - EXHIBIT 31.1 - Salarius Pharmaceuticals, Inc. | flks20171231ex-311.htm |
| 10-K - 10-K - Salarius Pharmaceuticals, Inc. | flks2017123110-k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-201816) pertaining to the 2014 Equity Incentive Plan, 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of Flex Pharma, Inc.; |
(2) | Registration Statement (Form S-8 No. 333-210283) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of Flex Pharma, Inc.; |
(3) | Registration Statement (Form S-8 No. 333-216534) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of Flex Pharma, Inc.; and |
(4) | Registration Statement (Form S-3 No. 333-210289) of Flex Pharma, Inc.; |
of our report dated March 7, 2018, with respect to the consolidated financial statements of Flex Pharma, Inc. included in this Annual Report (Form 10-K) of Flex Pharma, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP | ||
Boston, Massachusetts | ||
March 7, 2018 | ||